Aktuellt
SENASTE
Redeye provides an initial take on Optomed’s Q2 2023 report. Sales during the quarter amounted to EUR3.74m (EUR3.73m) compared to our sales estimate of EUR3.75m. Moreover, EBIT came in at EUR-1.0 (EUR-1.4m), and the cash position at the end of the period amounted to EUR5.7m. Overall, the report was in line with our expectations. We will provide a more in-depth update shortly, where we expect to only make minor changes in our short-term estimates and, therefore, do not expect to change our valuation.
LÄS MER
